Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as a once-daily oral tablet therapy.